Pattern of relapse/progression in lymphoblastic lymphoma
Patient no. . | Age, y . | Sex . | Regimen . | Mediastinal XRT? . | Response . | Months to relapse or progression* . | Initial sites of disease . | Sites of relapse . |
|---|---|---|---|---|---|---|---|---|
| 1 | 29 | F | M-HCVAD | N† | CR | 5 | M, pleural | M |
| 2 | 53 | M | M-HCVAD | N† | CR | 8 | M, nodes, CNS | Nodes |
| 3 | 37 | M | HCVAD | Y | CR | 12 | M, nodes | BM, CNS |
| 4 | 27 | M | HCVAD | Y | CR | 14 | M | BM |
| 5 | 28 | M | HCVAD | N | CR | 22 | M, pleural | M |
| 6 | 33 | M | HCVAD | N | CR | 23 | Nodes | Nodes |
| 7 | 23 | F | HCVAD | Y | CR | 27 | M, nodes | M, BM |
| 8 | 27 | M | HCVAD | Y | CR | 37 | M, nodes | CNS |
| 9 | 23 | M | M-HCVAD | N† | PR | 8 | M, CNS, pleural, pericardial | M, CNS |
| 10 | 44 | M | M-HCVAD | Y | PR | 12 | M, pleural | M, pleural, BM |
Patient no. . | Age, y . | Sex . | Regimen . | Mediastinal XRT? . | Response . | Months to relapse or progression* . | Initial sites of disease . | Sites of relapse . |
|---|---|---|---|---|---|---|---|---|
| 1 | 29 | F | M-HCVAD | N† | CR | 5 | M, pleural | M |
| 2 | 53 | M | M-HCVAD | N† | CR | 8 | M, nodes, CNS | Nodes |
| 3 | 37 | M | HCVAD | Y | CR | 12 | M, nodes | BM, CNS |
| 4 | 27 | M | HCVAD | Y | CR | 14 | M | BM |
| 5 | 28 | M | HCVAD | N | CR | 22 | M, pleural | M |
| 6 | 33 | M | HCVAD | N | CR | 23 | Nodes | Nodes |
| 7 | 23 | F | HCVAD | Y | CR | 27 | M, nodes | M, BM |
| 8 | 27 | M | HCVAD | Y | CR | 37 | M, nodes | CNS |
| 9 | 23 | M | M-HCVAD | N† | PR | 8 | M, CNS, pleural, pericardial | M, CNS |
| 10 | 44 | M | M-HCVAD | Y | PR | 12 | M, pleural | M, pleural, BM |
XRT indicates radiation therapy; M-HCVAD, modified hyper-CVAD; CR, complete remission; PR, partial response; M, mediastinum; pleural, pleural effusions; CNS, central nervous system; and BM, bone marrow.
From start of therapy.
Progression during intensive phase of chemotherapy prior to planned mediastinal XRT.